Diabetes mellitus (DM) is a metabolic disease characterised by hyperglycaemia because of insulin resistance or pancreatic β-cell failure (10). Glucagon-like peptide-1 (GLP-1) is an incretin hormone that mainly stimulates insulin secretion after oral food intake (11). It is a polypeptide synthesised from proglucagon, which is encoded by the glucagon or proglucagon gene (GCG). In addition to being used for synthesising GLP-1, proglucagon, which contains 160 amino acids, is used for synthesising glucagon, glicentin, oxyntomodulin, glicentin-related polypeptide (GRPP), and GLP-2 (13). Biologically active peptides are initially synthesised as protein precursors and are converted to their tissue- or cell-specific forms through post-translational processing (21). Enzymes belonging to the prohormone convertase family (PC1/3, PC2, PC4, PACE4, PC5/6, and PC7) regulate the post-translational processing of endocrine hormone precursors. Tissue-specific expressions of these enzymes result in the synthesis of different hormones from the same precursors. For instance, proglucagon is cleaved to glucagon by PC2 in pancreatic α-cells but is cleaved to GLP-1 by PC1/3 in intestinal L cells (2, 13, 16, 27).
GLP-1 is mainly produced by L cells, which are localised in the distal part of the intestine. The contact between the intestinal epithelium and glucose is important for inducing GLP-1 secretion (8). GLP-1 mainly targets pancreatic islet cells and exerts its effects through specific receptors (8, 30). In addition, GLP-1 exerts different effects on insulin secretion. First, GLP-1 directly stimulates insulin secretion through its receptors on pancreatic β-cells. Second, GLP-1 increases pancreatic β-cell proliferation by stimulating genes involved in cell proliferation and decreases the apoptosis of these cells by inhibiting caspase-3 expression. Furthermore, GLP-1 delays gastric emptying, suppresses glucagon secretion, and decreases gastrointestinal motility and nutrient ingestion (8, 12, 30).
Gastric inhibitor polypeptide and GLP-1 are important for the treatment and pathophysiology of diabetes because they increase postprandial insulin secretion (23). Secretion of GLP-1 increases the synthesis and secretion of insulin and maintains a balance between the apoptosis and proliferation of pancreatic β-cells in the pancreatic island, thus helping tissues to maintain their normal functions. In DM, reduced GLP-1 response to nutrient ingestion decreases insulin secretion (1, 4, 11). Moreover, defects in the post-translational processing of proglucagon in diabetes may reduce GLP-1 response to nutrient uptake. Exogenous GLP-1 administration normalises blood glucose levels in diabetic patients, indicating that GLP-1 plays a very active role both in the treatment and pathogenesis of diabetes (4, 11, 23).
In the present study on healthy and diabetic mouse ileum GLP-1 localisation and GCG gene expression were investigated by performing immunohistochemistry and a reverse transcription-polymerase chain reaction (RT-PCR), respectively.
Sequences of β-actin and proglucagon (GCG) specific primer pairs
Gene | Primers of genes | Reference number | |
---|---|---|---|
β-actin 5' | 5'-TCATGAAGTGTGACGTTGACATCCGT-3' | 20 | |
β-actin 3' | 5'-CCTAGAAGCATTTGCGGTGCACGATG-3' | 20 | |
Proglucagon | (GCG) 5' | 5'-GACTTCCCAGAAGAAGTCGCCAT-3' | 28 |
Proglucagon | (GCG) 3' | 5'-CTACGGTTACCAGGTGGTCATGT-3' | 28 |
PCR products obtained were electrophoresed on 1.5% agarose gel at 100 V for 1 h and were visualised by performing ethidium bromide staining. Bands obtained were visualised and photographed (DNR Bio-Imaging Systems, MiniLumi, Israel), and densitometric quantification was performed using ImageJ software version 1.4.3u. Densitometric findings for the GCG gene were normalised using those obtained for the β-actin gene, and the final data were used for performing statistical analysis.
Blood glucose level (mg/dL) on the 3rd day. Comparison among groups
Group | N | Blood glucose (mg/dL) minimum | Blood glucose (mg/dL) maximum | Blood glucose (mg/dL) mean ± SD |
---|---|---|---|---|
Diabetic | 6 | 240 | 360 | 275.66a ± 45.71 |
Control | 6 | 74 | 83 | 79.50b ± 3.27 |
Sham | 6 | 72 | 84 | 79.33b ± 4.13 |
a, b – values with different letters are significantly different (P < 0.05), N – number of mice, SD – standard deviation
Analysis of GLP-1 immunohistochemical localisation showed that a large number of GLP-1-immunopositive cells (L cells) was present between epithelial cells in the intestinal crypts and a small number of GLP-1-immunopositive cells was present between epithelial cells in the intestinal villi (Fig. 2). L cells were pyramidal in shape, were open-type endocrine cells, and their apical side faced the intestinal lumen (Fig. 3). Strong GLP-1 immunoreactivity was observed in the cytoplasm of L cells but was not observed in the muscularis mucosa or muscularis externa (Fig. 4). The intensity and localisation of GLP-1 immunoreactivity were similar among the mice from the three groups (Fig. 5). Moreover, GLP-1 immunoreactivity was not observed in the negative control sample (Fig. 6).
GLP-1 produced by the intestinal L cells is an incretin hormone that increases insulin concentration in the plasma after food ingestion. GLP-1 plays an important role in regulating blood glucose levels by enhancing insulin secretion, delaying gastric emptying, and decreasing glucagon secretion (22). In this study, diabetes did not change the expression of the GCG gene which encodes proglucagon. The study also yielded a determination of the location of the GLP-1-secreting L cells in the ileum.
The L cells of the intestinal mucosa, which exclusively express GLP-1, are mainly located in the distal part of the intestine,
The L cells present between the epithelial cells of the tunica mucosa are pyramidal in shape and contain several secretory granules. The apical side of these cells extends into the intestinal lumen, because of which these cells are called open-type enteroendocrine cells (1, 6, 9, 29). In the present study, we found that the L cells showed strong GLP-1 immunoreactivity in the cytoplasm, were pyramidal in shape, and were open-type endocrine cells because their apical region extended into the intestinal lumen. The extension of the apical region of the L cells into the intestinal lumen allows these cells to be in direct contact with nutrients, especially glucose.
GLP-1 is synthesised by the intestinal L cells through the post-translational processing of preproglucagon by PC enzymes, preproglucagon being encoded by the GCG gene (1, 7, 8, 13). GLP-1, whose synthesis depends on oral food intake, stimulates pancreatic β-cells to secrete insulin. The incretin effect of GLP-1 is markedly reduced in patients with DM (8, 11), which in turn decreases insulin secretion and promotes hyperglycaemia. Exogenous administration of GLP-1 normalises these parameters in diabetic patients, indicating that GLP-1 plays an important role in the pathogenesis of diabetes (4, 20).
Lugari
Although the incretin effect of GLP-1 decreases in patients with DM, it is unclear whether this decrease causes diabetes (8). The defect in the response to GLP-1 in diabetes may be because of a decrease in the number of β-cells or a disturbance in β-cell function (17, 18). In addition, increased expression and activity of dipeptidyl peptidase-IV (DPP-IV), which degrades circulating GLP-1, may decrease GLP-1 levels in diabetes (24). Some studies have reported that GLP-1 level decreases in diabetes (8, 23, 24); however, some other studies have reported that GLP-1 level increases with this affliction (25, 26). In contrast to both findings, Berghöfer
Many factors associated with insulin deficiency or resistance and hyperglycaemia play an important role in the pathogenesis of diabetes. Therefore, it is incorrect to conclude that diabetes is caused by a single factor. Many factors such as defective β-cell function, decreased β-cell number, increased DPP-IV expression or activity, and decreased circulating GLP-1 levels may contribute to the pathogenesis of diabetes.
In conclusion, the present study did not show any difference between the diabetic, sham, or control group mice with respect to GCG gene expression or GLP-1 localisation in the ileum, indicating that diabetes does not affect GCG gene expression or GLP-1 localisation in the ileum. In the future, we aim to examine a GLP-1 receptor.